Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership236,764 shares
Latest Disclosed Value $ 15,934,217
Barclays Plc ownership in 1HALO / Halozyme Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 236,764 shares of Halozyme Therapeutics, Inc. (IT:1HALO) valued at $13,699,165 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 308,223 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -23.18% during the quarter. The current value of the position is $13,855,429 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (1HALO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1HALO / Halozyme Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 236,764 -71,459 -23.18 15,934 -29.51 0.0038
2026-03-31 2025-09-30 13F/A-3 HALOZYME THERAPEUTICS COM 40637H109 308,223 12,688 4.29 22,605 47.04 0.0049
2026-03-19 2025-09-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 305,939 10,404 17,512 0.0046
2025-11-12 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 308,223 12,688 22,605 0.0049
2026-02-27 2025-06-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 295,535 45,617 18.25 15,374 -3.60 0.0035
2025-08-14 2025-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 295,535 45,617 15 0.0035
2025-08-13 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 295,535 45,617 15 0.0011
2026-03-17 2025-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 249,918 -100,072 -28.59 15,947 -4.70 0.0045
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 249,918 -100,072 16 0.0045
2026-03-19 2024-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 349,990 44,051 14.40 16,733 -4.44 0.0047
2025-02-13 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 349,990 44,051 17 0.0047
2026-03-31 2024-09-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 305,939 152,474 99.35 17,512 117.93 0.0046
2024-11-19 2024-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 305,939 152,474 18 0.0046
2024-11-15 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 305,939 152,474 18 0.0014
2026-03-23 2024-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 153,465 -131,114 -46.07 8,035 -30.59 0.0025
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 153,465 -131,114 8 0.0025
2026-03-24 2024-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 284,579 -126,119 -30.71 11,577 -23.74 0.0040
2024-05-15 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 284,579 -126,119 12 0.0040
2026-03-25 2023-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 410,698 196,346 91.60 15,179 85.38 0.0056
2024-02-15 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 410,698 196,346 15 0.0056
2026-03-26 2023-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 214,352 -66,470 -23.67 8,188 -19.16 0.0051
2023-11-07 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 214,352 -66,470 8 0.0051
2026-03-30 2023-06-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 280,822 86,194 44.29 10,129 36.29 0.0064
2023-09-20 2023-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 280,822 86,194 10 0.0064
2023-08-03 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 280,822 86,194 10 0.0064
2026-03-30 2023-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 194,628 77,974 66.84 7,433 11.98 0.0034
2023-05-04 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 194,628 77,974 7 0.0034
2026-03-30 2022-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 116,654 5,268 4.73 6,638 50.70 0.0030
2023-02-13 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 116,654 5,268 7 0.0030
2022-11-03 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 111,386 74,875 205.08 4,404 174.05 0.0048
2022-08-12 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 36,511 -37,937 -50.96 1,607 -45.89 0.0010
2022-05-16 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 74,448 -139,429 -65.19 2,970 -65.46 0.0023
2022-02-23 2021-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 213,877 79,476 59.13 8,599 57.32 0.0032
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 213,877 79,476 8,599 0.0032
2021-11-09 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 134,401 6,063 4.72 5,466 -6.21 0.0025
2021-08-13 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 128,338 -111,805 -46.56 5,828 -41.79 0.0028
2021-05-13 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 240,143 62,071 34.86 10,012 31.65 0.0054
2021-02-11 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 178,072 -56,965 -24.24 7,605 23.12 0.0040
2020-11-12 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 235,037 11,313 5.06 6,177 2.97 0.0037
2020-08-12 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 223,724 65,239 41.16 5,999 110.20 0.0046
2020-05-13 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 158,485 -25,515 -13.87 2,854 -12.51 0.0023
2020-02-10 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 184,000 83,622 83.31 3,262 109.51 0.0018
2019-11-15 2019-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 100,378 -6,610 -6.18 1,557 -15.33 0.0010
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 100,378 -6,610 1,557 359.9802
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 106,988 8,842 9.01 1,839 16.32 0.0011
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 98,146 52,927 117.05 1,581 138.82 0.0011
2019-02-14 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 45,219 -72,992 -61.75 662 -69.18 0.0005
2018-11-14 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 118,211 98,175 489.99 2,148 537.39 0.0015
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,036 -34,889 -63.52 337 -68.71 0.0003
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 54,925 -8,478 -13.37 1,077 -16.25 0.0008
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 63,403 23,612 59.34 1,286 85.84 0.0010
2017-11-14 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 39,791 -13,708 -25.62 692 0.87 0.0007
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 53,499 32,061 149.55 686 145.88 0.0007
2017-05-15 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 21,438 -10,996 -33.90 279 -12.81 0.0003
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 32,434 30,061 1,266.79 320 1,003.45 0.0003
2016-11-14 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,373 1,083 83.95 29 163.64 0.0000
2016-08-12 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,290 -10,101 -88.68 11 -89.32 0.0000
2016-05-16 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,391 -16,418 -59.04 103 -78.22 0.0002
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 27,809 -14,527 -34.31 473 -13.53 0.0006
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 42,336 40,160 1,845.59 547 1,039.58 0.0007
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,176 -2,001 -47.91 48 -18.64 0.0001
2015-05-19 2015-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 4,177 -7,421 -63.99 59 -43.81 0.0001
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 4,177 59
2015-02-13 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,598 -5,900 -33.72 105 -33.54 0.0001
2014-11-14 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 17,498 -12,682 -42.02 158 -41.91 0.0002
2014-08-14 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 30,180 -941 -3.02 272 -27.27 0.0003
2014-05-15 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 31,121 17,846 134.43 374 101.08 0.0004
2014-02-13 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 13,275 -12,802 -49.09 186 -35.42 0.0002
2013-11-14 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 26,077 -402,247 -93.91 288 -91.54 0.0003
2013-08-14 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 428,324 428,324 3,405 0.0042
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-05-13 2020-03-31 13F HALOZYME THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-10 2019-12-31 13F HALOZYME THERAPEUTICS OPT Call 14,900 -18.13 264 -6.38 n/a n/a n/a
2019-11-15 2019-09-30 13F/A HALOZYME THERAPEUTICS OPT Call 18,200 -10.34 282 -18.97 n/a n/a n/a
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS OPT Call 18,200 282 n/a n/a n/a
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS OPT Call 20,300 181.94 348 200.00 n/a n/a n/a
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS OPT Call 7,200 80.00 116 96.61 n/a n/a n/a
2019-02-14 2018-12-31 13F HALOZYME THERAPEUTICS OPT Call 4,000 59 n/a n/a n/a
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS OPT Call 67,200 3,260.00 1,316 3,109.76 n/a n/a n/a
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS OPT Call 2,000 41 n/a n/a n/a
2017-11-14 2017-09-30 13F HALOZYME THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS OPT Call 700 9 n/a n/a n/a
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-13 2014-12-31 13F HALOZYME THERAPEUTICS OPT Call 7,500 0.00 68 0.00 n/a n/a n/a
2014-11-14 2014-09-30 13F HALOZYME THERAPEUTICS OPT Call 7,500 0.00 68 0.00 n/a n/a n/a
2014-08-14 2014-06-30 13F HALOZYME THERAPEUTICS OPT Call 7,500 0.00 68 -24.44 n/a n/a n/a
2014-05-15 2014-03-31 13F HALOZYME THERAPEUTICS OPT Call 7,500 -81.25 90 -83.93 n/a n/a n/a
2014-02-13 2013-12-31 13F HALOZYME THERAPEUTICS OPT Call 40,000 117.39 560 177.23 n/a n/a n/a
2013-11-14 2013-09-30 13F HALOZYME THERAPEUTICS OPT Call 18,400 202 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-14 2018-12-31 13F HALOZYME THERAPEUTICS OPT Put 1,000 0.00 15 -16.67 n/a n/a n/a
2018-11-14 2018-09-30 13F HALOZYME THERAPEUTICS OPT Put 1,000 0.00 18 5.88 n/a n/a n/a
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS OPT Put 1,000 -99.41 17 -99.49 n/a n/a n/a
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS OPT Put 170,100 11,240.00 3,332 11,006.67 n/a n/a n/a
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS OPT Put 1,500 -99.40 30 -98.48 n/a n/a n/a
2013-11-14 2013-09-30 13F HALOZYME THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2013-08-14 2013-06-30 13F HALOZYME THERAPEUTICS OPT Put 248,100 1,972 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.